These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2131051)

  • 1. Flow cytometric evaluation of the cell cycle perturbations induced by S12363, a new vinca alkaloid derivative.
    Leonce S; Anstett M; Combe-Perez V; Pierre A
    Anticancer Drugs; 1990 Dec; 1(2):179-83. PubMed ID: 2131051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth inhibitory activity of S12363, a novel vinca alkaloid derivative on human melanoma cell lines.
    Tolis C; Photiou A; Camplejohn RS; Retsas S
    Anticancer Res; 1993; 13(1):161-6. PubMed ID: 8476208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of vinca alkaloids in enhancing the sensitivity of a methotrexate-resistant (L1210/R7A) line, studied by flow cytometric and chromosome number analysis.
    McGown AT; Poppitt DG; Swindell R; Fox BW
    Cancer Chemother Pharmacol; 1984; 13(1):47-53. PubMed ID: 6733842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Collateral sensitivity of a methotrexate-resistant L1210 cell line to the vinca alkaloids.
    Poppitt DG; McGown AT; Fox BW
    Cancer Chemother Pharmacol; 1984; 13(1):43-6. PubMed ID: 6733841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effects of vindesine, vinblastine, and vincristine on mitotic arrest and hormonal response of L1210 leukemia cells.
    Howard SM; Theologides A; Sheppard JR
    Cancer Res; 1980 Aug; 40(8 Pt 1):2695-700. PubMed ID: 6248211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetic analysis in living cells of the inhibition of the P-glycoprotein-mediated efflux of anthracyclines by vinca alkaloids.
    Pereira E; Tarasiuk J; Garnier-Suillerot A
    Chem Biol Interact; 1998 Jul; 114(1-2):61-76. PubMed ID: 9744556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between the cellular accumulation and the cytotoxicity of S12363, a new Vinca alkaloid derivative.
    Pierré A; Pérez V; Léonce S; Boutin JA; Saint-Dizier D; Hautefaye P; Lavielle G; Atassi G
    Cancer Chemother Pharmacol; 1992; 29(5):367-74. PubMed ID: 1551175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid.
    Kruczynski A; Barret JM; Etiévant C; Colpaert F; Fahy J; Hill BT
    Biochem Pharmacol; 1998 Mar; 55(5):635-48. PubMed ID: 9515574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of Vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil.
    Beck WT; Cirtain MC; Look AT; Ashmun RA
    Cancer Res; 1986 Feb; 46(2):778-84. PubMed ID: 3455678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative uptake, retention and action of vincristine, vinblastine and vindesine on murine leukaemic lymphoblasts sensitive and resistant to vincristine.
    Rivera-Fillat MP; Pallarés-Trujillo J; Domènech C; Grau-Oliete MR
    Br J Pharmacol; 1988 Apr; 93(4):902-8. PubMed ID: 3390658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxicity, cell cycle kinetics and morphonuclear-induced effects of Vinca alkaloid anticancer agents.
    Pauwels O; Kiss R; Pasteels JL; Atassi G
    J Pharm Pharmacol; 1995 Oct; 47(10):870-5. PubMed ID: 8583358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vinca-23-oyl amino acid derivatives: as new anticancer agents (review).
    Bhushana Rao KS; Collard MP; Trouet A
    Anticancer Res; 1985; 5(4):379-86. PubMed ID: 3898995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microfluorometric investigations on the cell cycle progression of experimental ascites tumors treated with alkaloidic drugs.
    Stöhr M; Fischinger W
    Arzneimittelforschung; 1978; 28(6):977-81. PubMed ID: 582007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro antagonism between cisplatin and vinca alkaloids.
    Lee K; Tanaka M; Kanamaru H; Hashimura T; Yamamoto I; Konishi J; Kuze F
    Br J Cancer; 1989 Jan; 59(1):36-41. PubMed ID: 2757923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental in vivo cross-resistance of vinca alkaloid drugs.
    Maral R; Bourut C; Chenu E; Mathe G
    Cancer Chemother Pharmacol; 1981; 5(3):197-9. PubMed ID: 7296754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of snail neurons in developing quantitative ultrastructural parameters for neurotoxic side effects of Vinca antitumor agents.
    Müller LJ; Moorer-van Delft CM; Zijl R; Roubos EW
    Cancer Res; 1990 Mar; 50(6):1924-8. PubMed ID: 2407348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological properties of a new alpha-aminophosphonic acid derivative of vinblastine.
    Pierré A; Lavielle G; Hautefaye P; Seurre G; Leonce S; Saint-Dizier D; Boutin JA; Cudennec CA
    Anticancer Res; 1990; 10(1):139-44. PubMed ID: 2334119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased schedule-dependent synergism of vindesine versus vincristine in combination with methotrexate against L1210 leukemia.
    Chello PL; Sirotnak FM
    Cancer Treat Rep; 1981; 65(11-12):1049-53. PubMed ID: 7296551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of a fluorescent methotrexate probe to monitor the effects of three vinca alkaloids on a mixed population of parental L1210 and gene-amplified methotrexate-resistant cells by flow cytometry.
    Poppitt DG; McGown AT; Fox BW
    Cancer Chemother Pharmacol; 1984; 13(1):54-7. PubMed ID: 6733843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of antibiotics and cancer chemotherapeutic agents on the cellular transport and antitumor activity of methotrexate in L1210 murine leukemia.
    Zager RF; Frisby SA; Oliverio VT
    Cancer Res; 1973 Jul; 33(7):1670-6. PubMed ID: 4124487
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.